Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Recruiting 5Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 43Thoracic 30Other hematologic neoplasm 23Sarcoma 9CNS 9Plasma cell 6Myeloid 5Other solid neoplasm 3Genitourinary 3Gastrointestinal 2Dermatologic 2Classical hematology 2Other neoplasm 1Endocrine 1

Conditions

Somatostatinoma 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 14Nivolumab 12Magnetic Resonance Spectroscopy 11pembrolizumab 10Specimen Handling 10Ipilimumab 9cabozantinib 8trametinib 6lenvatinib 6Temozolomide 6dabrafenib 4atezolizumab 4Lutetium-177 4Immunoglobulin G 4Everolimus 4Disulfides 4CTLA-4 Antigen 4selpercatinib 3Octreotide 3Cisplatin 3Carboplatin 3Capecitabine 3Bevacizumab 3entrectinib 2copper dotatate CU-64 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Vemurafenib 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Etoposide × Endocrine × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡